I studied with great interest the paper by Hemstreet et al. (1) . However, I disagree with the authors on several points. First, I disagree that " . . . approximately 20%-25% (of bladder cancers) are related to occupational exposure to chemicals, such as benzo [a] pyrene, benzidine, and ␤-naphthyamine . . . " (1) , because benzo[a]pyrene is not a recognized human bladder carcinogen (2, 3) .
Second, the authors cited articles [references 43-45 in (1) ] that stated that genetic changes in chromosomes 9 and 17 may play a role in bladder cancer development. However, there are several other chromosomes that have been implicated in bladder cancer development, including chromosome 11, which was originally mentioned in one of the references cited by Hemstreet et al. [ref- erence 43 in (1)]. Moreover, cytogenetic studies of transitional cell carcinomas, the most common bladder tumor, have not identified any single specific aberration (4) but have identified changes in chromosomes 1 (a wide variety of changes), 3, 5, and 10; trisomy of chromosome 7; and loss of one copy of chromosome 9 (4). The most likely candidates for a primary pathogenetic role in transitional cell carcinomas are trisomy of chromosome 7, monosomy of chromosome 9, and deletion of chromosome 10 (4). DNA-level studies [reviewed in (4) ] have shown that bladder cancer is also associated with losses of genetic material in chromosomes 9, 11, 17, 8, 4, and 13 (listed in order of decreasing frequency). Thus, the article by Hemstreet et al. (1) provided only limited information regarding cytogenetic changes associated with bladder cancer.
Third, if atypical and suspicious results in Table 2 (1) were considered to be positive, then the sensitivity of the Pap test in exposed workers would be much higher at the time of tumor diagnosis (70.8%).
It is my opinion that the authors minimized the role of genetic or cytogenetic testing as a biomarker for risk assessment in bladder cancer. Chromosomal aberration frequency in surrogate cells, such as lymphocytes, is a good predictor for cancer risk-subjects with high frequency of cytogenetic disorders are generally cancer prone (5) . The predictive value of cytogenetic testing would increase if the genetic anomalies were studied in target bladder cells (4) . For example, testing for the presence of micronuclei in exfoliated bladder cells obtained from urine is a very sensitive assay to identify subjects at high risk for bladder cancer (6) because micronuclei, which are bodies formed from whole or fragmented chromosomes, reflect either structural or numeric (or both) chromosomal aberrations. In addition, application of the fluorescent in situ hybridization (FISH) technique with probes for chromosomes 1, 5, 7, 9, 10, and Y [although in my opinion, probes for chromosomes 7, 9, and 10 are enough because other chromosomal abnormalities seem secondary and nonspecific (4)], which often contain genetic changes associated with bladder cancer, could possibly increase the specificity and sensitivity of micronucleus test for human bladder cancer risk assessment (7).
In conclusion, I suggest that the application of the micronucleus test and FISH technique for individual screening, monitoring, and diagnosis of occupationally exposed workers at risk for bladder cancer might be a more efficient approach than the molecular biomarkers proposed by Hemstreet et al. (1) 
RESPONSE
The comments by Dr. Nersesyan regarding cytogenetic biomarkers focus on a number of frequently underappreciated issues related to biomarker research. However, a central theme of the comments and our published work (1) is biomarker specificity and sensitivity. Potential biomarkers for bladder cancer, including chromosomal aberrations, and a meta-analysis of the more frequently used biomarkers have recently been reviewed (2, 3) . Currently, there are numerous promising biomarkers, but few have undergone phase II or III validation studies. In one phase II study, Halling et al. (4) compared cytology and fluorescence in situ hybridization (FISH) for the detection of genetic ploidy in urothelial carcinomas and reported that FISH had a sensitivity of 81% and a specificity of 96%. Similarly, Vysis Inc. (Downers Grove, IL) received U.S. Food and Drug Administration (FDA) approval to market FISH in a bladder cancer biomarker profile for detecting aneuploidy of chromosomes 3, 7, and 17 and loss of chromosome 9p21 and reported a sensitivity of 73.5%-75% and a specificity of 93% (package insert). The acceptance of FISH for chromosomal analysis and other tests depends on multiple parameters that relate primarily to the population studied, specificity, sensitivity, assay reliability, and cost [see references in (1)].
Most biomarkers for bladder cancer are evaluated initially in symptomatic patients and, thus, their performance for risk assessment, screening, and validation in asymptomatic patients remains to be determined. Although there are also encouraging clinical results with other biomarkers since the initiation of our study of Chinese workers in 1989 [see references in (1)], some markers, such as G-actin, that had shown great promise in earlier studies functioned poorly in later studies for as yet unknown reasons. This finding highlights the complexity of biomarker selection and evaluation. The two other biomarkers we focused on in our study (1) , p300 and DNA ploidy, have both stood the test of time, are approved by the FDA, and are commercially available in a number of boutique laboratories with accessible reagents.
Cytogenetic biomarkers are the result of inherited susceptibility factors and exposures and should be clearly distinguished from inherited genetic factors (5) . Of interest, the markers with high specificity and sensitivity appear to be associated with gross chromosomal aberrations or high-level phenotypic biomarkers, rather than point mutations. This observation is highly relevant to the mechanisms of bladder carcinogenesis, which may be elucidated by quantitative fluorescence image analysis. For example, because bladder cancers and most other solid tumors are heterogeneous, fluorescence imaging may assist in linking protein expression profiles to functional genomics by quantifying proteins expressed at the single cell level (proteomics).
Specificity is not only dependent on the methods but also on the cell type analyzed. Most clinicians consider atypical Pap cytology a major confounding report because of the poor specificity of the test. In our study (1) , the inclusion of atypical Pap results reduced the specificity of the biomarker profile. For this reason, biomarkers can be used to subclassify atypical cells, which, once again, stresses the importance of linking the cytologic, genetic, or phenotypic biomarkers to quantitative biophysical cytochemistry. In a subset of patients from our study of Chinese workers, Li evaluated peripheral blood lymphocytes and cytogenetic studies to detect bladder cancer and found the test to be tedious and, in general, lacking specificity (Li G: unpublished observation). However, these studies served to illustrate the differential susceptibility of a target organ to genetic damage and the relevance of studying functional genomics and proteomics in the context of a defined organ ecosystem.
In reference to benzo[a]pyrenes, they are currently under intense investigations as human carcinogens (6) . The 20%-25% cancer rate cited in our study (1) referred to occupational exposure overall and is the number frequently quoted (7).
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